Boston Partners acquired a new stake in Veracyte, Inc. (NASDAQ:VCYT – Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 661,382 shares of the biotechnology company’s stock, valued at approximately $30,357,000. Boston Partners owned approximately 0.82% of Veracyte at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in shares of Veracyte by 21.2% during the second quarter. GAMMA Investing LLC now owns 1,121 shares of the biotechnology company’s stock worth $66,000 after buying an additional 196 shares in the last quarter. Abel Hall LLC grew its stake in shares of Veracyte by 3.6% in the third quarter. Abel Hall LLC now owns 6,511 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 229 shares in the last quarter. Allworth Financial LP grew its stake in shares of Veracyte by 178.0% in the second quarter. Allworth Financial LP now owns 845 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 541 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Veracyte by 1.3% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 52,765 shares of the biotechnology company’s stock worth $2,429,000 after acquiring an additional 695 shares during the period. Finally, Eurizon Capital SGR S.p.A. bought a new position in Veracyte during the third quarter worth about $34,000.
Analysts Set New Price Targets
A number of analysts have issued reports on VCYT shares. Needham & Company LLC cut their price objective on shares of Veracyte from $69.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, November 5th. Weiss Ratings raised shares of Veracyte from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 16th. Wall Street Zen downgraded shares of Veracyte from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Morgan Stanley cut their price target on Veracyte from $47.00 to $44.00 and set an “underweight” rating for the company in a research note on Tuesday, August 4th. Finally, Zacks Research downgraded Veracyte from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $44.50.
Insider Activity at Veracyte
In other news, insider John Leite sold 4,015 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $40.00, for a total value of $160,600.00. Following the completion of the transaction, the insider owned 124,329 shares of the company’s stock, valued at $4,973,160. This represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jens Holstein sold 7,500 shares of Veracyte stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $50.00, for a total transaction of $375,000.00. Following the sale, the director owned 27,471 shares in the company, valued at approximately $1,373,550. This represents a 21.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 62,609 shares of company stock worth $2,858,904 over the last 90 days. 1.60% of the stock is currently owned by company insiders.
Veracyte Stock Up 0.2%
Veracyte stock opened at $25.09 on Friday. Veracyte, Inc. has a 12-month low of $21.91 and a 12-month high of $60.91. The business’s 50-day moving average price is $40.41 and its two-hundred day moving average price is $42.10. The stock has a market cap of $2.02 billion, a PE ratio of 16.19 and a beta of 1.98.
Veracyte (NASDAQ:VCYT – Get Free Report) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.10. The firm had revenue of $151.75 million during the quarter, compared to analysts’ expectations of $147.13 million. Veracyte had a net margin of 21.80% and a return on equity of 8.99%. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.51 earnings per share. As a group, analysts expect that Veracyte, Inc. will post 1.34 earnings per share for the current year.
Veracyte Company Profile
Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.
Further Reading
- Five stocks we like better than Veracyte
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
